International Biotechnology Trust

We discuss the opportunity as biotech stocks trade at record low valuations, despite strong prospects for the sector...

Add to watchlist Request a meeting Download View key data

Disclosure – Non-Independent Marketing Communication

This is a non-independent marketing communication commissioned by International Biotechnology. The report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on the dealing ahead of the dissemination of investment research.

International Biotechnology Trust

International Biotechnology Trust has seen a strong rebound in performance terms this year after performing relatively well versus peers in 2018, when a strong move toward ‘risk-off’ sentiment among investors saw equities generally in negative figures, with biotech no exception.

As at 7 May 2019, the trust is up 10.6% in NAV total return terms since the start of January, beating the NASDAQ Biotechnology Index, the peer group and its main rival – Biotech Growth Trust.

Last year, when the MSCI World was down 7.4% and the NASDAQ Biotechnology Index lost 3.2%, the trust lost just 4.4% - outperforming Biotech Growth, which lost 14.3%, by a whacking margin.

The four strong management team, led by Carl Harald Janson, aims to generate long term capital growth and deliver a yield of 4% of NAV via a portfolio of US, European and – to a lesser extent – unquoted investments in the biotech sphere.

In addition to the diversification benefits afforded by the trust’s scale, with almost 100 underlying holdings including the unquoted element, the trust’s unique focus on avoiding ‘binary’ risk events has helped it to avoid a number of ‘blowups’ which have affected its rivals, notably Biogen’s abandoned Alzheimer’s drug trials which saw it lose more than 30% of its market cap at the end of March this year.

The trust’s unquoted portfolio – where the emphasis has shifted from direct investments to investments via a venture fund – is already proving its worth, delivering 1.3x capital invested so far, with the vast majority of its holdings still valued at or close to their original investment value, leaving plenty of room for upside.

The trust has seen significant improvements to its share register, too, with far less concentration and a far broader spread of investors – among whom more than half are now private wealth managers or retail investors. Much of this has been driven by the introduction of a dividend policy which sees the trust pay out a yield of 4% of NAV per annum, converting some of the capital growth it generates to do so.

Whilst converting capital to income does limit the maximum potential for capital growth, the appeal of this yield means the trust has moved in from a persistent discount and now trades at a premium, and has been issuing new shares since Q4 last year – of which more than half a million have come to market. This should, in time, mean the trust’s ongoing charges ratio is lower as the trust’s fixed costs are spread over a wider shareholder base.

This is an interesting time for the trust. The managers believe that with economic growth on a fairly solid footing going forward, and long-term demand for therapeutic drugs driven by an ageing population, there is a secular tailwind behind biotech companies. We have heard from the trust before that a more ‘business friendly’ approach taken by the Food and Drugs Administration would lead to greater opportunities among biotech companies, and that seems to be playing out; last year saw more new drugs approved by the FDA than ever before.

Despite this, valuations among biotech companies remain very reasonable – particularly when compared with other sectors in the US. Indeed, while popular wisdom tells us that US equities are expensive after a long rally, the biotech sector is significantly cheaper in p/e terms than other major sectors in the US and far cheaper than the S&P500. Large cap biotech stocks are trading at record low p/e’s.

Large cap biotech valuations vs other US sectors

Source: Bloomberg, all sectors represented by S&P subsector definitions, updated through 4/8/19

Against this backdrop, and with mean reversion for biotech p/e ratios in mind, International Biotechnology is a compelling option for long-term growth and a solid income, with a clear – and clearly effective – approach to mitigating risk by avoiding ‘binary events’ where share price volatility is at its most dramatic. This latter feature particularly, given the biotech sector’s elevated risk profile, has obvious appeal.

Kepler View

The long-term demographic tailwind behind healthcare focused companies – as the developed world gets older and fatter, and expectations of better healthcare in the developing world increase in line with living standards – is clear. International Biotechnology Trust is a direct beneficiary of that trend, and we think the strength of the management team, particularly their practical experience in the industry – not just as investors – puts the trust in good stead to profit from it.

Biotech is a ‘risk-on’ sector, however, and drawdowns can be intense. We think the team deal with this well via their strategy of mitigating risk by diversification across sub-sectors, selecting therapeutic areas with defensive characteristics, avoiding large “elephants” accounting for any more than 10% of the portfolio, and avoiding binary events – divesting stock as companies approach crucial trials even if this means missing out on the last few yards of upside – but clearly investors should be aware that volatility is a feature of this strategy.

That said, the risk of drawdown is more than compensated by the potential upside – or has been in the past. The maximum drawdown for the trust over the last ten years was 26% - a relative trifle compared to the 385% it delivered over the same period in NAV terms. Particularly for investors with long time horizons, then, we think the trust has clear appeal.

BULL
BEAR
Biotech companies are knocking on an open door. Last year saw the highest number of drug approvals ever by the FDA and the new boss, Ned Sharpless – director of the National Cancer Institute – seems as pro-business as his predecessor.
Drawdowns for the trust and the sector can be severe
Offers a solid yield and good annualised returns, which haven’t been dented too much by the introduction of the income from capital policy
Biotech stocks are perceived as ‘risky’ and are likely to fall further and faster during any ‘risk off’ period for equities generally
A highly experienced manager who has a proven track record of outperformance supported by a strong and specialised team.

Pascal Dowling
Pascal is a partner at Kepler Partners LLP and launched Kepler Trust Intelligence when he joined Kepler in 2015. Prior to this he managed FE Trustnet, one of the UK's largest investment research websites, for ten years. In a former life Pascal was a financial journalist and he has written extensively about investment trusts and other investments for the trade and national press.

Fund History

Disclaimer

This report has been issued by Kepler Partners LLP.  The analyst who has prepared this report is aware that Kepler Partners LLP has a relationship with the company covered in this report and/or a conflict of interest which may impair the objectivity of the research.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise and you may get back less than you invested when you decide to sell your investments. It is strongly recommended that if you are a private investor independent financial advice should be taken before making any investment or financial decision.

Kepler Partners is not authorised to make recommendations to retail clients. This report has been issued by Kepler Partners LLP, is based on factual information only, is solely for information purposes only and any views contained in it must not be construed as investment or tax advice or a recommendation to buy, sell or take any action in relation to any investment.

The information provided on this website is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Kepler Partners LLP to any registration requirement within such jurisdiction or country. In particular, this website is exclusively for non-US Persons. Persons who access this information are required to inform themselves and to comply with any such restrictions.

The information contained in this website is not intended to constitute, and should not be construed as, investment advice. No representation or warranty, express or implied, is given by any person as to the accuracy or completeness of the information and no responsibility or liability is accepted for the accuracy or sufficiency of any of the information, for any errors, omissions or misstatements, negligent or otherwise. Any views and opinions, whilst given in good faith, are subject to change without notice.

This is not an official confirmation of terms and is not a recommendation, offer or solicitation to buy or sell or take any action in relation to any investment mentioned herein. Any prices or quotations contained herein are indicative only.  

Kepler Partners LLP (including its partners, employees and representatives) or a connected person may have positions in or options on the securities detailed in this report, and may buy, sell or offer to purchase or sell such securities from time to time, but will at all times be subject to restrictions imposed by the firm’s internal rules. A copy of the firm’s Conflict of Interest policy is available on request.

PLEASE SEE ALSO OUR TERMS AND CONDITIONS

Kepler Partners LLP is authorised and regulated by the Financial Conduct Authority (FRN 480590), registered in England and Wales at 9/10 Savile Row, London W1S 3PF with registered number OC334771.



Welcome to Kepler Trust Intelligence

Kepler Trust Intelligence is authorised in the UK by the Financial Conduct Authority.
Please enter a valid email address
{{item.msg}}
Please enter a valid password
{{item.msg}}
Please enter a valid email address
{{item.msg}}
Please check your email. If an account exists you'll be sent instructions on how to reset your password.
Kepler Trust Intelligence is authorised in the UK by the Financial Conduct Authority. To ensure that we are able to provide content which is appropriate for you, please tell us a little about yourself.
Please choose an option
{{item.msg}}
Please enter a company name
{{item.msg}}
Please enter a location name
{{item.msg}}
Please choose an option
{{item.msg}}
Please enter a platform
{{item.msg}}
Please choose an option
{{item.msg}}
Please enter a trust
{{item.msg}}
?
The information contained herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States to or for the benefit of any United States person (being residents of the United States or partnerships or corporations organised under the laws thereof). The investment funds referred to herein have not been registered in the United States under the Investment Company Act of 1940 and units or shares of such funds are not registered in the United States under the Securities Act of 1933.
Please confirm
{{item.msg}}
Please select an option
{{item.msg}}
See benefits
A free Kepler Trust Intelligence account allows you to access premium content including the ‘Kepler View’ – our verdict on the trusts we cover – and historical research so you can see how our view has changed over time. An account also unlocks useful facilities like the ‘follow’ button which lets you keep track of the trusts you’re interested in and as a logged in user you can also download PDFs of our research, and choose the layout of the page you’re reading to suit your preference. We will not share your details unless you give us permission to do so, and we won’t bombard you with emails – we only send one a week.
Please select an option
{{item.msg}}
Please enter your first name
{{item.msg}}
Please enter your last name
{{item.msg}}
Please enter a valid email address
An account already exists with this email - have you forgotten your password?
{{item.msg}}
Please enter a valid password
{{item.msg}}
Please enter a valid password
{{item.msg}}
How will this information be used? Your answers help us to tailor our content to relevant investment trusts, and to ensure that the asset allocation and portfolio strategy research we produce is appropriate to our userbase.
Our Website uses Cookies Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies, but parts of our site won’t work without them. By using our website you accept our use of cookies. For further information please refer to the Kepler Privacy Notice.
Need help?

One more thing...

Did you know, you can 'follow' individual trusts on Kepler Trust Intelligence? Use the functions below to set up alerts and we'll send you research and updates on your chosen trusts.

Suggested trusts to follow

Browse all funds
Need help?
Current Site Kepler Trust Intelligence is produced by the investment companies team at Kepler Partners and is the UK’s premier source of detailed qualitative research on investment trusts. Absolute Hedge is a market leading UCITS research database providing proprietary research on funds, themes and strategies in the UCITS space. Kepler Liquid Strategies is a Dublin domiciled UCITS fund platform featuring a number of best-of-breed fund managers. Kepler Partners is a corporate advisory and asset raising boutique specialising in the regulated funds market in Europe and investment trusts in the UK.